Immune checkpoint blockade, which involves targeting molecules such as programmed death-1 (PD-1)/PD-L1 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), can restore T cell function and reactivate anti-tumor immune responses [62,63]. This evidence concerns the gene CTLA4 and neoplasm.